{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:05:37Z","timestamp":1771041937410,"version":"3.50.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD011106"],"award-info":[{"award-number":["P51 OD011106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32 GM07215"],"award-info":[{"award-number":["T32 GM07215"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RR015459"],"award-info":[{"award-number":["RR015459"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RR020141"],"award-info":[{"award-number":["RR020141"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The rapid antigenic evolution of influenza viruses requires frequent vaccine reformulations. Due to the economic burden of continuous vaccine reformulation and the threat of new pandemics, there is intense interest in developing vaccines capable of eliciting broadly cross-reactive immunity to influenza viruses. We recently constructed a \u201cmosaic\u201d hemagglutinin (HA) based on subtype 5 HA (H5) and designed to stimulate cellular and humoral immunity to multiple influenza virus subtypes. Modified vaccinia Ankara (MVA) expressing this H5 mosaic (MVA-H5M) protected mice against multiple homosubtypic H5N1 strains and a heterosubtypic H1N1 virus. To assess its potential as a human vaccine we evaluated the ability of MVA-H5M to provide heterosubtypic immunity to influenza viruses in a non-human primate model. Rhesus macaques received an initial dose of either MVA-H5M or plasmid DNA encoding H5M, followed by a boost of MVA-H5M, and then were challenged, together with na\u00efve controls, with the heterosubtypic virus A\/California\/04\/2009 (H1N1pdm). Macaques receiving either vaccine regimen cleared H1N1pdm challenge faster than na\u00efve controls. Vaccination with H5M elicited antibodies that bound H1N1pdm HA, but did not neutralize the H1N1pdm challenge virus. Plasma from vaccinated macaques activated NK cells in the presence of H1N1pdm HA, suggesting that vaccination elicited cross-reactive antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Although HA-specific T cell responses to the MVA-H5M vaccine were weak, responses after challenge were stronger in vaccinated macaques than in control animals. Together these data suggest that mosaic HA antigens may provide a means for inducing broadly cross-reactive immunity to influenza viruses.<\/jats:p>","DOI":"10.1371\/journal.pone.0181738","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T17:43:36Z","timestamp":1501782216000},"page":"e0181738","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques"],"prefix":"10.1371","volume":"12","author":[{"given":"Kelsey R.","family":"Florek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attapon","family":"Kamlangdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Mutschler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brock","family":"Kingstad-Bakke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Schultz-Darken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl W.","family":"Broman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-6895","authenticated-orcid":true,"given":"Thomas C.","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"pone.0181738.ref001","unstructured":"WHO (2014) Influenza (Seasonal) Fact Sheet N211. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/ via the Internet. Accessed x."},{"key":"pone.0181738.ref002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"MT Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"pone.0181738.ref003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/595861","article-title":"Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004\u20132005 season to the 2006\u20132007 season","volume":"199","author":"EA Belongia","year":"2009","journal-title":"J Infect Dis"},{"key":"pone.0181738.ref004","first-page":"20","article-title":"Antigenic variation in influenza viruses","volume":"8","author":"GM Air","year":"1987","journal-title":"Contrib Microbiol Immunol"},{"key":"pone.0181738.ref005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/jinf.2000.0652","article-title":"Influenza virus: a master of metamorphosis","volume":"40","author":"JC De Jong","year":"2000","journal-title":"J Infect"},{"key":"pone.0181738.ref006","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"F Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0181738.ref007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","article-title":"Immunogenicity and protective efficacy of influenza vaccination","volume":"103","author":"C Hannoun","year":"2004","journal-title":"Virus Res"},{"key":"pone.0181738.ref008","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"D Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"key":"pone.0181738.ref009","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1210724","article-title":"Biochemistry. Catching a moving target","volume":"333","author":"TT Wang","year":"2011","journal-title":"Science"},{"issue":"Suppl 2","key":"pone.0181738.ref010","first-page":"B5","article-title":"Global Vaccine Action Plan. Decade of vaccine collaboration","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"pone.0181738.ref011","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.it.2011.08.007","article-title":"Targeting B cell responses in universal influenza vaccine design","volume":"32","author":"K Kaur","year":"2011","journal-title":"Trends Immunol"},{"key":"pone.0181738.ref012","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"F Krammer","year":"2013","journal-title":"J Virol"},{"key":"pone.0181738.ref013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The Quest for a Universal Flu Vaccine: Headless HA 2.0","volume":"18","author":"F Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"pone.0181738.ref014","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"AH Ellebedy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0181738.ref015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DJ DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"pone.0181738.ref016","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DJ DiLillo","year":"2016","journal-title":"J Clin Invest"},{"key":"pone.0181738.ref017","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection","volume":"19","author":"CJ Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"pone.0181738.ref018","doi-asserted-by":"crossref","first-page":"e1005578","DOI":"10.1371\/journal.ppat.1005578","article-title":"Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection","volume":"12","author":"GS Tan","year":"2016","journal-title":"PLoS Pathog"},{"key":"pone.0181738.ref019","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1128\/JVI.01219-14","article-title":"Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques","volume":"88","author":"NW Florek","year":"2014","journal-title":"J Virol"},{"key":"pone.0181738.ref020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"W Fischer","year":"2007","journal-title":"Nat Med"},{"key":"pone.0181738.ref021","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1128\/JVI.01532-14","article-title":"Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene","volume":"88","author":"A Kamlangdee","year":"2014","journal-title":"J Virol"},{"key":"pone.0181738.ref022","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1128\/JVI.00730-16","article-title":"Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses","volume":"90","author":"A Kamlangdee","year":"2016","journal-title":"J Virol"},{"key":"pone.0181738.ref023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/erv.09.148","article-title":"Animal models for the preclinical evaluation of candidate influenza vaccines","volume":"9","author":"R Bodewes","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"pone.0181738.ref024","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal Models for Influenza Virus Pathogenesis and Transmission","volume":"2","author":"NM Bouvier","year":"2010","journal-title":"Viruses"},{"key":"pone.0181738.ref025","doi-asserted-by":"crossref","first-page":"e78750","DOI":"10.1371\/journal.pone.0078750","article-title":"A novel nonhuman primate model for influenza transmission","volume":"8","author":"LH Moncla","year":"2013","journal-title":"PLoS One"},{"key":"pone.0181738.ref026","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"SJ McConkey","year":"2003","journal-title":"Nat Med"},{"key":"pone.0181738.ref027","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","article-title":"Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis","volume":"24","author":"SC Gilbert","year":"2006","journal-title":"Vaccine"},{"key":"pone.0181738.ref028","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time","volume":"9","author":"MA Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"pone.0181738.ref029","doi-asserted-by":"crossref","first-page":"e1002381","DOI":"10.1371\/journal.ppat.1002381","article-title":"Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates","volume":"7","author":"JT Weinfurter","year":"2011","journal-title":"PLoS Pathog"},{"key":"pone.0181738.ref030","unstructured":"(1996) Guide for the care and use of laboratory animals."},{"key":"pone.0181738.ref031","unstructured":"Weatherall D (2006) The use of non-human primates in research: a working group report."},{"key":"pone.0181738.ref032","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","article-title":"Compact, synthetic, vaccinia virus early\/late promoter for protein expression","volume":"23","author":"S Chakrabarti","year":"1997","journal-title":"Biotechniques"},{"key":"pone.0181738.ref033","unstructured":"(2002) Manual on Animal Influenza Diagnosis and Surveillance."},{"key":"pone.0181738.ref034","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1073\/pnas.1200039109","article-title":"Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses","volume":"109","author":"N Pica","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0181738.ref035","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1128\/JVI.03030-12","article-title":"Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques","volume":"87","author":"S Jegaskanda","year":"2013","journal-title":"J Virol"},{"key":"pone.0181738.ref036","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.1128\/JVI.01650-12","article-title":"A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays","volume":"86","author":"MD Alpert","year":"2012","journal-title":"J Virol"},{"key":"pone.0181738.ref037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00335-010-9247-9","article-title":"Genetic resistance to diet-induced obesity in chromosome substitution strains of mice","volume":"21","author":"LC Burrage","year":"2010","journal-title":"Mamm Genome"},{"key":"pone.0181738.ref038","volume-title":"Multiple Testing Procedures with Applications to Genomics","author":"S Dudoit","year":"2007"},{"key":"pone.0181738.ref039","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/JVI.02335-08","article-title":"Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus","volume":"83","author":"DJ Laddy","year":"2009","journal-title":"J Virol"},{"key":"pone.0181738.ref040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/infdis\/jiu529","article-title":"Avian influenza A(H5N1) and A(H9N2) seroprevalence and risk factors for infection among Egyptians: a prospective, controlled seroepidemiological study","volume":"211","author":"MR Gomaa","year":"2015","journal-title":"J Infect Dis"},{"key":"pone.0181738.ref041","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1222526","article-title":"The potential for respiratory droplet-transmissible A\/H5N1 influenza virus to evolve in a mammalian host","volume":"336","author":"CA Russell","year":"2012","journal-title":"Science"},{"key":"pone.0181738.ref042","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"CJ Wei","year":"2010","journal-title":"Science"},{"key":"pone.0181738.ref043","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/vaccines3020239","article-title":"Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head","volume":"3","author":"LC Wiersma","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"pone.0181738.ref044","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1038\/ncomms7553","article-title":"Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck","volume":"6","author":"H Zaraket","year":"2015","journal-title":"Nat Commun"},{"key":"pone.0181738.ref045","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"S Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0181738.ref046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"L Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"pone.0181738.ref047","first-page":"321","article-title":"The FcgammaR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies","volume":"382","author":"PM Hogarth","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"pone.0181738.ref048","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"A Morell","year":"1970","journal-title":"J Clin Invest"},{"key":"pone.0181738.ref049","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12026-014-8541-0","article-title":"Primary and long-term B-cell responses in the upper airway and lung after influenza A virus infection","volume":"59","author":"AW Boyden","year":"2014","journal-title":"Immunol Res"},{"key":"pone.0181738.ref050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/mi.2015.38","article-title":"Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice","volume":"9","author":"A Lemke","year":"2016","journal-title":"Mucosal Immunol"},{"key":"pone.0181738.ref051","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2004-07-2507","article-title":"Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response","volume":"105","author":"M Odendahl","year":"2005","journal-title":"Blood"},{"key":"pone.0181738.ref052","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jiw262","article-title":"Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge","volume":"214","author":"S Jegaskanda","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0181738.ref053","doi-asserted-by":"crossref","first-page":"13706","DOI":"10.1128\/JVI.01666-13","article-title":"Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques","volume":"87","author":"S Jegaskanda","year":"2013","journal-title":"J Virol"},{"key":"pone.0181738.ref054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"TK Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0181738.ref055","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.vaccine.2013.01.038","article-title":"Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice","volume":"31","author":"JN Brewoo","year":"2013","journal-title":"Vaccine"},{"key":"pone.0181738.ref056","doi-asserted-by":"crossref","first-page":"e88340","DOI":"10.1371\/journal.pone.0088340","article-title":"MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses","volume":"9","author":"A Hessel","year":"2014","journal-title":"PLoS One"},{"key":"pone.0181738.ref057","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"H Meyer","year":"1991","journal-title":"J Gen Virol"},{"key":"pone.0181738.ref058","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"JH Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"pone.0181738.ref059","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.vaccine.2016.02.028","article-title":"Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored \u2026","volume":"34","author":"J Mullin","year":"2016","journal-title":"Vaccine"},{"key":"pone.0181738.ref060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nm0695-583","article-title":"Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus","volume":"1","author":"JJ Donnelly","year":"1995","journal-title":"Nat Med"},{"key":"pone.0181738.ref061","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0264-410X(96)00280-0","article-title":"Immunization of non-human primates with DNA vaccines","volume":"15","author":"MA Liu","year":"1997","journal-title":"Vaccine"},{"key":"pone.0181738.ref062","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","article-title":"DNA vaccines: progress and challenges","volume":"175","author":"JJ Donnelly","year":"2005","journal-title":"J Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T21:12:36Z","timestamp":1654204356000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181738"}},"subtitle":[],"editor":[{"given":"Stefan","family":"P\u00f6hlmann","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0181738","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}